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practice points
 ●  A normal cycling cell can encounter up to 30,000 DNA damage events in 1 day, which are repaired by distinct 
pathways that target and repair specific lesions.
 ●  Platinum-based chemotherapeutics exert toxicity through the formation of irreparable base adducts and DNA 
crosslinks, which direct the cancerous cells towards apoptotic death.
 ●  The selective pressure exerted on the tumor eventuates genetic drift and may provide the cancerous cells 
resistance to many anticancer therapies.
 ●  Several distinct while overlapping pathways exist within the cell to detect and repair the various DNA damage 
lesions that may occur.
 ●  The inaccurate repair of DNA lesions may lead to mutations within the cell and drive tumorigenesis.
 ●  Many cancers contain mutations in DNA repair genes, for example, more than 90% of small cell lung cancers and 
50% of all non-small-cell lung cancers carry mutations in tP53, encoding the important tumor suppressor, p53.
 ●  Many anticancer therapies, including platinum-based chemotherapeutics and replication inhibitors, induce 
apoptosis within the cell through the formation of irreparable DNA damage.
 ●  The deregulation of DNA repair proteins within cells may provide an attractive therapeutic window. Such an 
approach is exemplified by the PARP inhibitors, which show potential use in the treatment of cancers deficient 
of functional BRCA1 or BRCA2. In addition, these drugs may show increased efficacy in combination with 
DNA-damaging agents.
 ●  Resistance to platinum-based agents may be acquired through multiple mechanisms, including mutation or 
deregulation of DNA repair proteins, alteration of membrane transport protein activity and chromatin remodeling.
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Lung cancer is the leading cause of cancer-
related mortality worldwide, with a 5-year 
survival rate of approximately 15% [1]. Despite 
considerable optimism regarding the advent of 
targeted therapies and personalized medicine, 
the current first-line treatment for most lung 
cancer patients remains combinational thera-
pies using cytotoxic chemotherapeutic agents 
[2]. In particular, the platinum-based DNA-
damaging agents cisplatin and carboplatin form 
the foundation of many lung cancer treatment 
regimes. These drugs are selectively cytotoxic 
to rapidly dividing cells, where they cause an 
overwhelming level of irreparable DNA damage, 
subsequently directing cells towards apoptotic 
cell death [3]. However, despite a typical initial 
efficacy, the primary challenge with these agents 
remains the eventual development of drug resist-
ance, the precise mechanisms of which remain 
poorly understood.
In normal noncancerous cells, stability of the 
genomic code is largely maintained through the 
combined activities of a vast array of DNA repair 
proteins. These proteins act to detect damages to 
the code, initiate cell cycle checkpoint signaling, 
and either repair the lesion, or if too extensive, 
activate apoptotic pathways. In cancerous cells, 
regulation of these processes is progressively 
lost, leading to an accumulation of mutations 
[4]. Furthermore, while deregulation of DNA 
repair most likely contributes to initial malignant 
transformation of the cell, continued mutation 
as a result of this loss may facilitate the progres-
sion to metastatic disease. This may occur as a 
result of the high selective pressure experienced 
by the cell, including the necessity to function 
in a foreign environment (e.g., a foreign tissue).
As such, genomic instability is one of the 
major hallmarks of cancer; this is especially 
true of lung malignancies, which display 
some of the highest rates of genetic change [5]. 
Here, instability is largely driven by deregula-
tion of the DNA damage repair pathways, as 
well as of downstream cell cycle checkpoints. 
Deregulation of the DNA repair system com-
bined with the selective pressures experienced 
by the malignant cells, enables the selection for 
clonal populations of cancer cells from within a 
tumor mass. It is through this process of tumor 
evolution that eventually yields a tumor mass 
that is spatially and genetically heterogeneous 
[6,7]. This genetic diversity presumably allows 
tumors to respond relatively quickly to environ-
mental changes, including the encounter of anti-
cancer therapies. This said, while genetic insta-
bility may function as an important governor of 
cancer cell plasticity, deregulation of the DNA 
damage repair pathways renders the cancer cells 
more sensitive to DNA-damaging agents [8–10]. 
This sensitivity represents an attractive thera-
peutic window, targetable by various anticancer 
chemo- and radio-therapies.
As suggested above, the loss of genomic sta-
bility is an important hallmark of cancer devel-
opment. In a large number of cases, this may 
result from accumulated mutations in the genes 
of DNA repair proteins, suggesting an indirect 
mechanism of carcinogenic compound muta-
genicity. Cigarette smoking, for example, has 
been convincingly implicated as a causal agent 
for the development of lung cancer [11]. Cigarette 
smoke contains over 70 known carcinogens, 
many of which may directly alter the genetic 
code [11]. This elevated degree of stress may 
result in a process termed ‘accelerated genomic 
aging’ whereby the DNA-damage repair capac-
ity of the cell is no longer balanced with the 
rate of DNA damage occurrence, resulting in 
the failure to correctly repair DNA adducts and 
the subsequent gain of mutations.
In the current review, we present an overview 
of the known mechanisms of DNA damage 
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summary Lung cancer is the leading cause of cancer-related mortality. According to 
WHO, 1.37 million deaths occur globally each year as a result of this disease. More than 70% 
of these cases are associated with prior tobacco consumption and/or cigarette smoking, 
suggesting a direct causal relationship. The development and progression of lung cancer 
and other malignancies involves the loss of genetic stability, resulting in acquisition of 
cumulative genetic changes; this affords the cell increased malignant potential. As such, an 
understanding of the mechanisms through which these events may occur will potentially 
allow for development of new anticancer therapies. This review will address the association 
between lung cancer and genetic instability, with a central focus on genetic mutations in the 
DNA damage repair pathways. In addition, we will discuss the potential clinical exploitation 
of these pathways, both in terms of biomarker staging, as well as through direct therapeutic 
targeting.
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repair, and examine how deregulation of these 
processes may contribute to disease progression 
in cancer. We then conclude with a discussion 
on the therapeutic potential of these pathways in 
future anticancer treatment regimes.
DNa damage & genomic instability in lung 
cancer
A normal cycling cell may receive up to 30,000 
DNA damage events each day. This can include 
oxidation or deamination of DNA bases, the for-
mation of nucleotide photo adducts, covalent 
inter- or intra-strand crosslinkage of DNA, as 
well as the generation of ssDNA and dsDNA 
breaks [12–15]. DNA breaks are primarily the 
result of endogenous processes, including 
somatic and meiotic recombination, reaction 
with reactive oxygen species that arise from 
normal cellular metabolism, and the collapse 
of stalled DNA replication forks. These breaks 
can also occur via exogenous insult, such as 
from exposure to radiation and chemothera-
peutics, as well as to carcinogenic environmental 
compounds [13,16–18].
Of the approximately 5000 compounds com-
prising cigarette smoke, 73 have been identified 
as carcinogenic, with 20 specifically affecting 
the lungs. Many of these compounds appear 
mutagenic through a direct interaction with 
the DNA. For instance, carcinogens such as α-, 
β-unsaturated aldehydes (enals) and formalde-
hyde covalently modify DNA, forming various 
DNA lesions [19]. Furthermore, the majority of 
carcinogens in cigarette smoke are metaboli-
cally activated within the cell through oxidiza-
tion reactions [20]. This leads to the generation 
of electrophilic compounds that may attack 
nucleophilic sites on DNA bases [20], leading 
to covalent lesion formation. Site mutations 
may then occur as a result of the cells inability 
to correctly repair these adducts. For example, 
in vitro and in vivo studies have associated 
exposure to polycyclic aromatic hydrocarbons 
(PAH) with TP53 and KRAS mutations in lung 
cancer [11].
human DNa repair pathways
In order to cope with the genomic stresses 
mentioned above, the cell employs a diverse 
array of DNA repair proteins. To date, over 
160 proteins have been identified that partici-
pate in this process [21]. These proteins func-
tion in a series of distinct yet inter-related 
pathways to repair each specific form of DNA 
lesion [22,23]. Specifically, there are five distinct 
major DNA repair pathways in human cells. 
These are base excision repair (BER), nucleo-
tide excision repair (NER), mismatch repair 
(MMR), nonhomologous end-joining (NHEJ), 
and homology-directed repair (HDR), as rep-
resented in figure 1. Defects in each pathway 
are associated with specific mutations observed 
in lung cancer.
●● oxidative DNa damage & BeR
More than 100 different oxidative base modifi-
cations have been identified in the mammalian 
genome, the most prevalent and well charac-
terized of which is 7,8-dihydro-8-oxo-guanine 
(8-oxo-G) [24]. The estimated steady state level 
of 8-oxo-G in human cells is approximately 
103 lesions per cell/per day in normal tissues 
and up to 105 lesions per cell/per day in tissues 
that have become cancerous [25]. These lesions 
are highly mutagenic, as they may base pair 
equally with cytosine and adenine, thereby 
increasing the frequency of G to T substitu-
tions [25]. The repair of 8-oxo-G DNA dam-
age is therefore critical in maintaining DNA 
integrity. Furthemorer, G:C to A:T transver-
sion mutations have been identified as the most 
predominant somatic mutations in lung, breast, 
ovarian, gastric and colorectal cancer [26].
Oxidative DNA damage is repaired primar-
ily by the BER pathway (figure 1D). However, 
accumulating evidence suggests that the NER 
pathway may also play a role (figure 1a) [14,27]. 
Here, histone deacetylases have been suggested 
to regulate important cellular oxidative stress 
pathways, including those required for sensing 
oxidative lesions and regulating the subsequent 
cellular response [28].
The BER machinery consists of more than 
20 proteins that function through two major 
subpathways, short-patch BER and long-patch 
BER [29]. While contrasts do exist between 
the two pathways, a basic model for the BER 
mechanism may be considered as: lesion 
recognition/strand scission; gap tailoring and; 
DNA synthesis/ligation [29]. Initiation of each 
pathway occurs through the action of specific 
DNA glycosylases (e.g., OGG1, NTHL1 and 
NEIL3), which recognize and excise the dam-
aged base, leaving an abasic site [14,27]. APE1 
may then cleave the phosphodiester backbone 
5′ to the abasic site, leaving a free 3′ hydroxyl 
group for polymerase-mediated replacement of 
the nucleotide. Depending on the BER type, 
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either the single damaged base (short patch) 
or multiple downstream nucleotides (long 
patch) are then replaced, and the gap ligated. 
While the XRCC1/DNA ligase III heterodi-
mer facilitates ligation during short-patch BER, 
the FEN1 and DNA ligase I allow gap closure 
during long-patch BER [14].
Although BER is able to remove the major-
ity of oxidative lesions prior to replication, in 
some instances damages are able to sustain into 
S-phase. As mentioned above, these lesions 
may then be incorrectly base paired by replica-
tive DNA polymerases (δ and ε), which may 
incorporate adenine in place of cytosine com-
plementary to the adduct. As hOGG1, the major 
human DNA glycosylase involved in 8-oxo-G 
removal, is only able to efficiently remove these 
lesions base paired with cytosine, a second BER 
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figure 1. DNa repair pathways. (a) Repair of bulky adducts through the NER pathway. (B) Mismatch repair of insertions and deletions 
that occur during replication. (C) Repair of dsDNA breaks by HDR or nonhomologous end joining. (D) ssDNA break repair. 
BER: Base-excision repair; HDR: Homology-directed repair; NER: Nucleotide excision repair.
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pathway is required to correct the mismatch in 
cases of incorrect adenine incorporation [30]. 
This pathway is initiated by the monofunc-
tional MutY homolog DNA glycosylase (also 
referred to as hMYH), which seems specific for 
the removal of an adenine opposite the 8-oxo-G 
lesion [14].
●● Bulky DNa adducts & NeR
Helix-distorting DNA adducts may arise 
from either endogenous or exogenous DNA-
damaging events, including exposure to UV 
radiation (resulting in the formation of cyclob-
utane pyrimidine dimers and pyrimidine-[6,4]-
pyrimidone photoproducts), as well as chemical 
alkylating agents such as the PAHs present in 
cigarette smoke or charcoaled meat [31]. Bulky 
DNA adducts are predominately repaired by the 
NER pathway (figure 1a), a series of enzymatic 
reactions facilitated by at least 30 proteins. Of 
significant interest to the treatment of lung can-
cer is the observation that NER is required for 
the repair of cisplatin DNA lesions [32].
NER consists of two subpathways, transcrip-
tion-coupled NER (TC-NER), which is used 
to repair damage in the actively transcribed 
strand, and global genome NER, which is a 
slower process that continuously scans and 
repairs DNA damage throughout the genome 
[33]. Both pathways consist of multiple steps, 
including: DNA damage recognition; recruit-
ment of the preincision protein complex and 
DNA unwinding; excision of the damaged 
fragment and; DNA repair synthesis and liga-
tion [33]. In TC-NER, the damage signal is 
initiated by RNA polymerase II, which stalls 
at damage sites, allowing for recruitment of 
Cockayne syndrome complementation group 
A and B, which subsequently initiate the onset 
of TC-NER [31]. In global genome NER, 
damage recognition is mediated by the XPC/
hHR23B, and DDB1 and DDB2/XPE com-
plexes [34]. Following damage recognition, the 
NER pathways converge to repair the lesion. 
Here, helix unwinding by TFIIH (XPB, XPD, 
p62, p52, p44, p34 and p8) allows verifica-
tion of damage by the preincision complex 
(XPD, XPB, XPA and XPG) [31]. Excision of a 
24–32-nucleotide section including the dam-
age is then facilitated by the joint activities 
of the XPG and CPF-ERCC1 endonucleases. 
DNA synthesis by DNA polymerases δ, ε and 
κ, in conjunction with PCNA, RPA and RPC, 
then allows replacement of the excised strand; 
the phosphodiester backbone is then sealed by 
DNA ligase I [31].
The GC-NER recognition factor XPC has 
been demonstrated to have a strong involve-
ment in lung cancer etiology. For instance, in 
one study, XPC null mice were found to develop 
multiple spontaneous benign lung tumors, with 
a minority progressing to adenocarcinomas 
with metastasis to adjacent lymph nodes [35]. 
In addition, XPC is a target for allelic loss in 
the majority of both small- and non-small-cell 
lung carcinomas. These losses occur early in the 
progression to lung tumorigenesis, suggesting 
that XPC allelic loss might be a driver event 
[35]. Several polymorphisms in XPC have also 
been associated with increased risk of lung can-
cer development, such as Lys939Gln, which has 
been shown to correlate with a significant risk 
of lung cancer development [36].
●● Mismatch repair
The DNA MMR pathway is a highly conserved 
mechanism that recognizes and repairs errone-
ous insertions, deletions and base substitutions 
that escape the proofreading function of DNA 
polymerases during DNA replication [37]. As 
with other repair pathways, MMR takes place 
in several steps: mismatch recognition; excision 
and; gap filling and ligation (figure 1B). Initially, 
the mismatch is recognized by one of two 
MutS heterodimers: MutSα (MSH2/MSH6), 
which detects small base errors, or MutSβ 
(MSH2/MSH3), which binds larger mismatches 
[38]. This facilitates activation of MutL com-
plexes α or γ (MutLα: MLH1/PMS2; MutLγ: 
MLH1/MLH3), which recruit to the site, and in 
concert with PCNA and RFC, nick the strand 
5′ to the mismatch [39]. Exo1, which possesses 
5′–3′ exonuclease activity, is then able to degrade 
the strand, leading to the formation of a ssDNA 
gap [40]. The excised strand is then resynthesized 
by DNA polymerase δ, and ligated by DNA 
ligase I [38].
Inactivation of MMR induces a mutator 
phenotype and causes predisposition to cancer. 
Indeed, mutations in the human MMR genes 
MSH2 and MLH1 are associated with heredi-
tary nonpolyposis colorectal cancer [41], which 
is characterized by early onset (<45 years) and 
the presence of neoplastic lesions in a variety of 
tissues including the endometrium, skin, ova-
ries, stomach and kidneys. A hallmark of MMR-
deficient cells is microsatellite instability, which 
is widely used as a diagnostic marker for loss of 
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MMR activity in tumor cells [42]. Although lung 
cancer exhibits high levels of microsatellite insta-
bility, it is as yet unclear if defects in MMR play 
a role in this phenotype. A recent study, however, 
did provide evidence that aberrant expression 
of MLH1 is associated with EGFR mutations 
in non-small-lung cancer (NSCLC), suggesting 
that expression changes in this pathway may 
contribute to the observed genetic instability [43].
●● dsDNa breaks
dsDNA breaks (DSBs) are one of the most 
toxic and mutagenic DNA lesions experienced 
by the cell (figure 2). DSBs are repaired either 
by the error-prone process of NHEJ, or by 
the error-free process of HDR (figure 1C) [44]. 
NHEJ involves the rejoining of either side of a 
DSB. Although the majority of these rejoining 
events will maintain the genetic code, instances 
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figure 2. DNa damage signaling resulting in cell cycle arrest. (a) Sensors of DNA damage identify DNA lesions and initiate signaling. 
(B) Transducers amplify and regulate the signal, resulting in the activation of effector proteins. (C) The effector proteins stimulate 
checkpoint arrest and activate proteins involved in DNA repair. Dotted lines represent crossover between the ATM and ATR cell cycle 
check point pathways.  
MRN: Mre11/Rad50/Nbs1 complex.
review Burgess, Croft, Wallace et al.
future science group
165
where either end is damaged may result in loss 
of nucleotides; thus, NHEJ is regarded as an 
imprecise DNA repair pathway [45]. In either 
case, one of the earliest requirements for the 
signaling of DSBs is the phosphorylation of 
histone H2AX at serine 139, forming a prod-
uct referred to as γH2AX [46]. This event is 
predominantly facilitated by the ATM kinase, 
although may also be affected by the other 
major DNA repair PI3K-related kinases, ataxia 
telangiectasia and Rad3-related kinase (ATR), 
and DNA-dependent protein kinase catalytic 
subunit (DNA-PK
cs
) [47].
During NHEJ, the ring-shaped Ku protein 
heterodimer (Ku70/Ku80) binds tightly at 
each DSB termini and is important in recruit-
ing DNA-PK
cs
; together these proteins form 
the active DNA-PK catalytic complex [48]. The 
interaction of DNA-PK complexes on either side 
of the break is then thought to bridge the DNA 
break, concurrently triggering autophosphoryl-
ation of the DNA-PK
cs
 subunit and subsequent 
dissociation of the complex. At this point, end 
joining may occur either through the ligation of 
existing microhomologies on either side of the 
break or of blunt-ended termini. In instances 
where incomplete microhomologies exist, gap 
filling may be required by DNA polymerases 
μ and/or λ [49]. In addition, these enzymes 
may function in the production of blunt ends, 
where they may ‘fill in’ 3′ ssDNA overhangs. 
Alternatively, where 5′ ssDNA overhangs exist, 
DNA-PK may recruit and activate the Artemis 
nuclease, which subsequently digests these 
strands through 5′–3′ exonuclease activity 
[50,51]. Finally, the scaffolding protein XRCC4 
stimulates DNA ligase IV to bind and ligate 
the opposing DNA ends, restoring the integ-
rity of the molecule. Ligation may be further 
enhanced by the XLF/Cernunos factor [52].
Unlike NHEJ, which functions throughout 
all stages of the cell cycle, the most common 
HDR called homologous recombination (HR) 
is only active during the S and G2 phases, due 
to the necessity of a sister chromatid for use 
as a homologous template [44,53]. Although a 
number of HDR subtypes exist (classical DSB 
repair via the Holliday junction, synthesis-
dependent strand annealing and single strand 
annealing), each is initiated by resection of 
the DSB 5′ ssDNA strand. Of central impor-
tance to this process is the Mre11/Rad50/Nbs1 
(MRN) complex, which nicks the strand up to 
3 kb from the break site and digests it in the 
3′–5′ direction [54–56]. This is complemented 
by the 5′–3′ exonuclease activities of exo1 and 
Dna2, which digest the strand away from the 
site of damage. In each type of HR, the exposed 
ssDNA strand is then rapidly bound by replica-
tion protein A (RPA), which facilitates loading 
of the RAD51 recombinase; this coated strand 
is referred to as a presynaptic filament. Rad51 
may then facilitate homology searching and 
invasion of the strand into a sister chromatid, 
allowing repair by complementarity [57,58].
While HR and NHEJ are largely capable 
of maintaining integrity of the chromosome, 
instances where a concentrated series of DSBs 
occur may trigger large-scale chromosomal 
rearrangements, a condition known as chromo-
thripsis [59]. This most likely occurs through the 
incorrect ligation of the overwhelming number 
of break termini, and may result in large dele-
tions, as well as rearrangements both between 
and within chromosomes [59].
genetic mutations in lung cancer
As discussed above, effective repair of damaged 
DNA is central to maintaining the integrity 
of the genetic code, including preventing the 
accumulation of genetic mutations that may 
otherwise lead to malignant transformation. 
However, in some instances, the DNA repair 
pathways may be overwhelmed, such as by expo-
sure to carcinogenic compounds (e.g., those 
found in cigarette smoke). This may result in 
loss of genomic integrity and the eventual gain 
of driver mutations, including oncogene activa-
tion and/or loss of tumor suppressor function.
Lung cancer has one of the most aggressive 
mutation rates of all cancers. This was recently 
highlighted through a screen of somatic muta-
tions in protein kinase genes from 210 cancer 
cell lines, which demonstrated an average muta-
tion rate of 4.21 per megabase [26]. In addi-
tion, Ding et al., sequenced 188 primary lung 
adenocarcinomas and identified a total of 26 
significantly mutated genes including many 
already known tumor suppressors, for exam-
ple TP53, KRAS, CDKN2A and STK11 [60]. 
Whole-genome and transcriptome sequencing 
has also revealed high mutation levels in DNA 
repair genes, including CDNK2 (p16) and RB 
[61,62].
More than 90% of small cell lung cancers 
(SCLCs) and 50% of all non-small-cell lung 
cancers (NSCLCs) carry mutations in the 
tumor suppressor protein p53 gene, TP53. 
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The presence of TP53 mutations in preneo-
plastic lesions in the lung indicates that TP53 
mutation is an early event in the progression of 
lung cancer [63]. p53, considered the ‘guardian 
of the genome’, responds to cellular stresses, 
including DNA damage, and regulates the 
expression of target genes to activate cell cycle 
arrest, DNA repair, or, if DNA damage is 
irreparable, to induce apoptosis [64]. Loss of p53 
tumor suppressor function leads to deregulated 
proliferation and increased genomic instabil-
ity, evidenced by the accumulation of genetic 
errors [65]. In particular, loss of p53 function 
has been linked to an increase in mutations 
resulting from HDR.
Interestingly, differential TP53 coding tran-
sitions exist in tumors isolated from smokers 
and nonsmokers. For example, while G-T 
transitions have been identified in 12% of non-
smokers, up to 30% of smokers may develop 
these mutations [66,67]. Conversely, while G to A 
transitions have been observed in tumors from 
47% of nonsmokers, only 29% of smokers dis-
play this alteration. Interestingly, these muta-
tions are not randomly distributed across the 
TP53 gene, with hotspots existing in codons 
157, 158, 245, 248, 249 and 273 [66,68,69]. While 
the cause of these mutations remain unknown, 
PAH diol epoxide metabolites found in ciga-
rette smoke is known to favourably react at 
these hotspots in tobacco-related lung cancers 
[66,68–69].
Particularly common in lung cancer is the 
loss of heterogeneity at chromosome 3p21.3, 
an occurrence seen in 60% of NSCLC. 
Furthermore, a number of studies suggest that 
in these cells, allele loss at 3p21.3 may actu-
ally be the earliest premalignant change in 
lung cancer development [70]. Interestingly, 19 
candidate tumor suppressor genes are found 
within a minimal 370 kb region at this locus 
[71], and it has been suggested that these func-
tion together as a tumor suppressor group [72]. 
In addition, deletion mutations are frequently 
observed in or near locus p21 of chromosome 9, 
within proximity to the coding sequence of the 
cyclin dependent kinase inhibitor, p16. This 
region presumably represents a ‘fragile site’ 
within the genome, where NHEJ processing 
of DSBs formed following collapse of replica-
tion forks may account for the introduction of 
mutations [73].
NHEJ is also implicated in chromosomal 
rearrangements (inversions and translocations) 
that fuse various 5´ partners with the 3´ kinase 
domain of ALK, as has been described in sev-
eral malignancies including NSCLC. In 3–5% 
of lung cancer, these rearrangements produce 
an aberrant EML4–ALK chimeric fusion pro-
tein with constitutive oncogenic kinase activity 
[74]. Another common fusion partner for ALK is 
KIF5B, a protein also involved in translocations 
with the RET proto-oncogene and TFG [75,76].
DNa repair pathways as biomarkers 
& therapeutic targets
In the previous sections we have reviewed the 
complexities of the DNA damage repair path-
ways, as well as the mutational consequences 
of aberrations in these processes in lung cancer. 
In the following sections we review the impor-
tance of these pathways in a clinical setting and 
the effects these mutations may have (Table 1).
The treatment of lung cancer is primarily 
through the administration of chemotherapeu-
tics, where surgery and radiation may also be 
used for early-stage tumors. The effectiveness 
of chemotherapeutic treatment relies on the 
exploitation of a therapeutic window, whereby 
the tumor cell will exhibit a higher degree of 
toxicity than the normal cells of the patient. 
These therapeutic windows are, however, often 
small, and substantial management is required 
to control toxicity to the patient.
The induction of DNA damage is a cen-
tral premise of many anticancer treatments 
[120]. For instance, genotoxicity of the nucleic 
acid mimic gemcitabine is presumably caused 
by incorporation of this drug into the DNA, 
causing disruption of polymerase progression 
and subsequent generation of DSBs through 
the collapse of stalled replicative forks [121]. 
Similarly, platinum-based chemotherapeutics 
may react with the DNA, where they cause 
crosslinking of nucleotides and similarly stall 
replicative fork migration [3]. Alternatively, the 
topoisomerase II inhibitor etoposide prevents 
unwinding of the double helix ahead of the 
replicative machinery, preventing exposure of 
single-stranded DNA for polymerase-mediated 
replication [122]. Other drugs, such as peme-
trexed and methotrexate, reduce the availability 
of deoxyribonucleotides, inducing replicative 
stress [123]. Unfortunately, while these drugs 
often show initial efficacy, acquired resistance 
to these agents frequently occurs. The mecha-
nisms through which this may eventuate are 
discussed in later sections.
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Table 1. Major mutated/deregulated DNa repair genes in lung cancer.
gene function Mutation/deregulation effect of gene mutation/deregulation Risk
XRCC1
 
 
Coordinator of oxidative damage 
repair through DNA ligase III, 
DNA polymerase and poly 
(ADP-ribose) polymerase [77]
Arg 399 Gln Controversial data – potential 
increased risk of cancer [77–82]
 
Arg 194 Trp Sensitivity to platinum [83,84] OR: 1.19 [85]
Arg 280 His Increased risk of lung cancer OR: 1.4 [85]
eRCC1
 
 
Rate-limiting role in the 
nucleotide excision repair 
pathway that recognises and 
removes cisplatin DNA adducts
Alterations in ERCC1 
expression levels
ERCC1 mRNA levels predict sensitivity 
to cisplatin [86,87]
Hazard ratio: 0.6 [87]
Low expression Increased sensitivity to PARP inhibitors 
[88]
 
rs3212986 A Significantly associated with increased 
risk of death from NSCLC [89]
 
OGG1 8-oxoguanine-DNA glycosylase 
required for the repair of 
oxidative damage-induced 
mutations
Ser 326 Cys Increased risk of lung cancer Twofold increase in 
risk of lung cancer 
[90–92]
MUtYH Required for repair of oxidative 
damage-induced mismatches
Gln 324 His Increased risk of lung cancer [93] OR: 3.3 [93]
aPe1
 
Required for repair of small base 
lesions
Thr 656 Gly
Increased expression
Increased risk among smokers [94,95]
Increased resistance to cisplatin
OR: 1.342 [96]
83.3% (20 out of 24) 
of cisplatin-resistant 
tumors show high 
APE1 expression 
levels [97]
NBS1 A component of the MRN 
complex required for double 
strand break repair [98–100]
Glu 185 Gln Increased risk of lung cancer OR: GluGln/GlnGln 
vs GluGlu: 1.21 [101]
eXO1
 
Endonuclease required NER, 
HDR and mismatch repair
Glu 589 Lys Increased risk of lung cancer in 
smokers
OR: 1.72 [102]
 
In vivo depletion Desensitized cells to paclitaxel [12]
BRCa1
 
Required for the repair of DSBs 
[16,17,103,104]
Mutated Lower expression providing a better 
outcome in lung cancer patients [105]
Increase in 
resistance to a 
wide range of 
DNA-damaging 
agents and radiation 
therapy [106–109]
  Low expression of BRCA1pS1423 was 
associated with a worse survival [110]
atM
 
 
ATM acts as a central mediator of 
the radioprotective machinery, 
participating in cellular stress 
responses, control of cell cycle 
checkpoints, repair of DSBs, and 
initiation of apoptosis
Ser 62160 Gly>Ala Higher risk of lung cancer than those 
with the G allele
OR: 1.6 [111]
Ser 227060 T Increased risk of lung cancer OR: 1.55 [112]
Ser 170548 C Increased risk of lung cancer OR: 1.51 [112]
p53 Plays a role in apoptosis, 
genomic stability, and inhibition 
of angiogenesis [94–95,113]
Frequently mutated or 
inactivated, including 
homozygous deletions and 
abnormally sized messenger 
RNAs, as well as a variety of 
point or small mutations
Mutations lead to poorer patient 
prognosis and decreased survival [114]
 
Ku70/80
 
Involved in numerous cellular 
processes including apoptosis, 
regulation of specific gene 
transcription, regulation of heat 
shock-induced responses and 
telomere maintenance [115–118]
Ku70 (rs2267437) Increased risk of lung cancer OR: 1.32 [119]
Ku80 (rs3835) Increased risk of lung cancer OR: 1.44 [119]
DSB: dsDNA break; HDR: Homology-directed repair; MRN: Mre11/Rad50/Nbs1 complex; NER: Nucleotide excision repair; NHEJ: Nonhomologous end-joining; NSCLC: Non-small-cell 
lung cancer; OR: Odds ratio.
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synthetic lethality
One of the most important therapeutic 
approaches of current interest is that of synthetic 
lethality. Originally termed from the study of 
cellular pathways in Saccharomyces cerevisiae 
and Drosophila melanogaster, synthetic lethal-
ity refers to the loss of cell viability through the 
mutation of genes in parallel pathways, which, 
when disrupted separately, do not result in mor-
tality [124]. In terms of cancer treatment, such 
an approach may be applied whereby cell death 
is induced through the manipulation of targets 
complementary to those mutated in the tumor 
[125,126]. A current example of this is inhibition of 
PARP DNA repair enzymes in cells deficient of 
functional BRCA1 or BRCA2. PARP enzymes 
are central to both the repair of SSBs and DSBs 
[127], where they catalyze the covalent attach-
ment of ADP-ribose onto glutamic acid residues 
of a substrate protein in an NAD+-dependent 
manner [128,129]. When PARP function is inhib-
ited, such as by the small-molecule inhibitor 
olaparib, the SSBs normally repaired by PARP 
are converted to DSBs. Although these would 
typically be repaired by DSB repair pathways, 
in BRCA1- or BRCA2-deficient tumors, the 
HDR pathway no longer functions effectively, 
leading to the overwhelming incidence of DSBs 
and subsequent apoptotic cell death [130]. As the 
noncancerous cells possess a functioning HDR 
pathway, cell death is not similarly induced 
outside of the tumor.
Early studies into PARP inhibitors using ini-
parib however failed to prolong survival in its 
first Phase III trial in metastatic triple-negative 
breast cancer, despite promising Phase II results 
[131]. As iniparib has since been revealed not to 
function as a PARP inhibitor as first suggested, 
the potential for inhibitors of this class remains 
[132]. Indeed, there are currently a number of 
alternative PARP inhibitors undergoing clini-
cal trials. Veliparib (ABT-888), for instance, 
is currently in Phase II testing in a multicenter 
first-line randomized trial in unselected patients 
with NSCLC (n = 120) [133,134]. Veliparib sen-
sitivity has previously been demonstrated in 
mouse xenografts of B-cell lymphoma and small- 
and non-small cell lung carcinoma, as well as 
cancers of the pancreas, ovaries, breast and pros-
tate, where numerous regressions were observed 
[135]. Clark et al. have suggested that combina-
tion treatment of veliparib and carboplatin (a 
DNA-damaging platinum-based compound) 
may be more successful than monotherapy in 
addressing many BRCA-associated cancers [125].
Olaparib (AZD 2281; AstraZeneca, London, 
UK) is an oral PARP inhibitor that has shown 
potency in BRCA-mutated breast cancers, as well 
as in ovarian cancers with or without BRCA1 or 
BRCA2 mutations [136]. Furthermore, enhance-
ment of radiosensitization by olaparib was 
observed in cell lines regardless of the p53 sta-
tus, similar to that observed for another PARP 
inhibitor, MK-4827 [137]. This suggests that low 
dose olaparib treatment may enhance tumor sen-
sitivity to radiation treatments (the induction of 
DNA damage) [138]. Work in lung cancer cells 
has also suggested protein levels of ERCC1, an 
important component of the NER pathway, may 
be predictive of olaparib and veliparib sensitiv-
ity, both as single agents and in combination 
with cisplatin [88]. Furthermore, the ERCC1 
rs3212986 AA allele is significantly associated 
with poor survival of NSCLC in comparison to 
the CC, a reference variable genotype. Another 
potential predictor of PARP inhibitor effectivity 
may involve OGG1. OGG1 has been shown to 
bind directly to PARP-1 [139], and interestingly 
OGG1-/- mouse embryo fibroblasts have been 
reported to be more sensitive to PARP inhibitors 
than those which are OGG1+/+ [139].
Drug resistance in lung cancer
Resistance to chemotherapeutics and selective 
targeted agents is ultimately the leading cause 
of cancer-related death [140]. In the instance of 
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gene function Mutation/deregulation effect of gene mutation/deregulation Risk
XRCC4 Binds to DNA and to DNA ligase 
IV involved in NHEJ
rs1805377 Increased risk of lung cancer OR: 2.38 [119]
DNa 
ligase IV
X-family DNA polymerase with 
5´-deoxyribose-5-phosphate 
(dRp) lyase activity, but lacks 
exonuclease activity
rs1805388 Increased risk of lung cancer OR: 1.64 [119]
DSB: dsDNA break; HDR: Homology-directed repair; MRN: Mre11/Rad50/Nbs1 complex; NER: Nucleotide excision repair; NHEJ: Nonhomologous end-joining; NSCLC: Non-small-cell 
lung cancer; OR: Odds ratio.
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platinum-based agents, such as cisplatin, car-
boplatin and oxaliplatin, resistance may occur 
through a number of means, including alteration 
of pathways involved in both preventing and 
repairing DNA damage [141]. As such, one of the 
prominent characteristics of cisplatin resistance 
is the reduced accumulation of cisplatin within 
the cell due to deregulation of membrane trans-
porters or binding proteins, which seemingly 
allow decreased influx or increased efflux of the 
drug [142,143]. Here, the influx of cisplatin seems 
to be mediated largely by CTR1. Indeed, while 
expression of this protein is seen to increase in 
platinum-sensitive cells treated with cisplatin, a 
suppression of this protein is observed in resist-
ant cells. In addition to CTR1, TMEM205 and 
GLUT1 have also been implicated in resistance 
to cisplatin [144].
Chromatin remodeling/modification may 
also be involved in chemotherapy resistance. For 
example, overexpression of PIWIL2, a member 
of the PIEI/Argonaute gene family and a key reg-
ulator of chromatin modification, has been sug-
gested to facilitate cisplatin resistance in some 
cancers, presumably as a result of chromatin 
condensation [145]. In addition, altered expres-
sion of various histone acetyltransferases may 
also provide platinum resistance. For instance, 
TIP60 overexpression has been observed in 
cisplatin-resistant lung cancer cells [146].
Epigenetic profiling of two pairs of cispl-
atin-resistant cell lines also revealed the down-
regulation of several hundred genes, which could 
be reactivated by the DNA methytransferase 
inhibitor, 5-aza-2´-deoxycytidine [141]. This 
suggested that DNA methylation-mediated gene 
regulation might be a common and potentially 
important mechanism of cisplatin resistance. 
Additionally, DNA that is more condensed is 
less solute exposed, and thus will presumably 
encounter reduced incidence of cisplatin adduct 
formation.
Once a cisplatin adduct forms, the cell may 
either repair the lesion through the NER, BER 
or HDR DNA damage repair pathways, or acti-
vate apoptosis signaling as a result of detection 
by the MMR proteins. As such, it is reasonable 
to expect deregulation of DNA damage repair 
is a likely mechanism of cisplatin resistance. 
Indeed, the upregulation of a number of these 
proteins is observed in cells resistant to platinum 
compounds. ERCC1, for example, is upregu-
lated in a number of cisplatin-resistant ovarian 
cancer cell lines [147]. This is complemented by 
significantly prolonged survival of patients with 
ERCC1-negative tumors [89].
Conclusion & future perspective
Genomic instability is not only the driver of lung 
cancer initiation, but is also a hallmark of dis-
ease progression. Furthermore, exogenous and 
endogenous pressures that also drive continued 
tumor evolution select for cells with increased 
genetic instability and suppressed apoptotic 
signaling. This process eventually yields a 
genetically diverse tumor that also commonly 
results in resistance to anticancer therapies. 
As described in this review, genetic stability is 
maintained in normal cells through a number 
of distinct while inter-related pathways, the 
disruption of which may lead to accumulation 
of genetic mutations. However, while it is the 
loss of DNA repair capacity that initiates tumo-
rigenesis, deregulation of these repair pathways 
also presents a potential therapeutic window. 
This has been highlighted by targeted thera-
pies, including the PARP inhibitors veliparib 
and olaparib, which selectively target cells with 
a suppressed ability to repair DSBs, for example 
those absent of functional BRCA1 or BRCA2. 
In addition, these drugs may show increased effi-
cacy when employed in combination with geno-
toxic stress agents inductive of replication fork 
stalling. As such, continued research into the 
roles and regulation of the DNA damage repair 
pathways, as well as their disruption in cancer, 
will likely provide new therapeutic targets in 
subsequent years.
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